Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria

Infection. May-Jun 1991;19(3):186-9. doi: 10.1007/BF01643250.

Abstract

The in vitro activity of cefepime and SCE-2787, two new parenteral cephalosporins, and the combination effect with tobramycin and gentamicin against nosocomial gram-negative rods was studied using checkerboard agar dilution technique. Cefepime showed excellent in-vitro activity against Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens and Proteus vulgaris (MIC90 0.03-0.125 mg/l) and good to moderate activity against Acinetobacter anitratus, Pseudomonas aeruginosa and Pseudomonas cepacia (MIC90 4-16 mg/l). SCE-2787 had an excellent activity against Citrobacter spp. (MIC90 0.125 mg/l) and a very good activity against A. anitratus, P. aeruginosa and P. vulgaris (MIC90 1-2 mg/l). Pseudomonas maltophilia was not inhibited at therapeutically achievable concentrations (MIC90 64 mg/l). On average, 14-28% of the strains were inhibited by synergistic SCE-2787 aminoglycoside-combinations, whereas only 8.6% were inhibited by a synergistic effect of the combination with cefepime and gentamicin. No antagonism occurred with any of the combinations.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Cefepime
  • Cephalosporins / pharmacology*
  • Cross Infection / microbiology
  • Drug Therapy, Combination / pharmacology
  • Gentamicins / pharmacology
  • Gram-Negative Bacteria / drug effects*
  • Humans
  • Microbial Sensitivity Tests
  • Tobramycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Gentamicins
  • cefozopran
  • Cefepime
  • Tobramycin